智通财经APP获悉，中国银河证券发布研报称，持续重点强调生猪养殖行业的攻守兼备布局机会，基于 能繁母猪作用值及养殖效率的考虑，26年猪价同比下行，期间或有所反弹表现;综合考虑政策去产能以 及行业亏损去产能，重点关注成本边际变化显著、资金面良好的优质猪企。另可关注养殖链后周期及动 物疫苗相关企业。考虑黄羽鸡自身供给相对低位，叠加需求端的改善预期。宠物食品行业处成长过程 中，优质企业市占率呈提升趋势。 宠物食品：25年出口略承压，呈现量增价跌特征 12月我国宠物食品出口额9.06亿元，同比-2.91%。其中出口量3.77万吨，同比+15.49%;出口均价24.02 元/kg，同比-15.93%，刷新年内低点。25年出口额101.02亿元，同比-4.1%;出口量36.13万吨，同比 +7.8%;出口均价27.96元/kg，同比-11%。 2月农业指数表现弱于沪深300 2月农林牧渔指数-0.14%，同期沪深300上涨0.09%。养殖业(+1.02%)涨幅相对居前，而农产品加工 (-3.23%)、动物保健(-3.27%)表现相对靠后。 生猪养殖：2月猪价震荡下行，自繁自养再度亏损 2月11日猪价12.75元/kg，较 ...

每经头条（nbdtoutiao）——中美大反转，中国AI调用量首超美国，A股嗨了，多板块掀涨停潮！华尔 街知名分析师：中国算力路径颠覆传统认知 （记者 王晓波） 每经AI快讯，申联生物2月27日晚间发布2025年度业绩快报，营业收入约2.88亿元，同比减少4.99%；归 属于上市公司股东的净利润亏损1909.07万元；基本每股收益亏损0.05元。上年同期营业收入约3.03亿 元；归属于上市公司股东的净利润亏损4474.01万元；基本每股收益亏损0.11元。 ...

申联生物表示，公司实现减亏的主要原因为2024年度公司对在研项目计提了减值；同时，在行业市场竞 争激烈的情况下，公司产品和营销取得积极进展，同时费用管控更加精细有效。 （文章来源：北京商报） 北京商报讯2月27日晚间，申联生物（688098）发布2025年度业绩快报显示，报告期内，公司实现营业 收入约为2.88亿元，同比下降4.99%；归属净利润-1909.07万元，同比实现减亏。 ...

经济观察网 普莱柯披露多项产品研发进展，并将召开临时股东会审议董事选举事项。 股票近期走势截至2026年2月27日收盘，普莱柯股价报14.24元，当日上涨0.99%，近5日累计上涨 2.45%；当日成交额8444万元，换手率1.71%。资金流向方面，2月27日主力资金净流入约308万元，而2 月26日主力资金曾净流出309万元，占当日成交额6.98%。股价波动区间内最高触及14.37元，最低为 13.79元。 机构观点机构综合目标价为17.00元，较当前价格存在约20%的上涨空间。根据盈利预测，2025年公司 净利润同比增速预计达101.14%，营收同比增长14.65%。近期机构评级以中性为主，调研频率较低。 以上内容基于公开资料整理，不构成投资建议。 近期事件普莱柯于2026年2月24日在投资者互动平台披露研发进展，公司多款禽腺病毒系列联苗已获得 新兽药注册证书并推向市场；禽流感重组杆状病毒载体三价灭活疫苗、猪伪狂犬病活疫苗等近10项产品 已通过新兽药注册初审或进入复核检验阶段；另有数款产品处于临床试验或实验室研究阶段。此外，公 司公告将于2026年3月6日召开临时股东会，审议选举第六届董事会董事及独立董事 ...

据国家统计局数据，截至2025年末，全国生猪存栏42,967万头，比上年末增加224万头，同比增长 0.5%。报告期内，面对竞争日益激烈的市场环境，公司管理层与全体员工团结一心、锐意进取、攻坚 克难，持续加大研发力度，加快新产品研发进展，不断提升市场竞争力，带动收入和利润稳步增长。 格隆汇2月27日丨科前生物(688526.SH)公布2025年度业绩快报，2025年公司实现营业收入9.50亿元，较 上年增加0.89%；实现归属于母公司所有者的净利润4.16亿元，较上年增加8.70%。 ...

内容概要：禽用疫苗是预防禽类传染病的关键生物制剂，是现代家禽养殖业疫病防控的基石。国家出台 多项政策，从全产业链构建严密监管体系，为行业筑牢质量安全防线，推动产品升级，激活市场需求。 中国作为禽类养殖与消费大国，家禽生产平稳发展，出栏量增长、存栏量优化，为禽用疫苗市场提供坚 实需求基础，催生高端疫苗市场扩容空间。禽肉产量稳健增长，拉动防疫投入，禽蛋产量调整促使精准 化免疫模式转变，共同推动禽用疫苗市场规模扩张与产品结构升级。随着畜牧业发展，兽用生物制品市 场规模扩大，2024年禽用生物制品市场复苏增长。禽用疫苗细分市场中，灭活疫苗主导，活疫苗稳基， 其他疫苗高速扩容。未来，行业将在多重驱动下高质量发展，多联多价疫苗成研发主流，新型疫苗技术 商业化加快，行业集中度提升，并向综合服务模式转型，国内企业也将加快国际化布局。 上市企业：中牧股份（600195.SH）、瑞普生物（300119.SZ）、普莱柯（603566.SH）、生物股份 （600201.SH） 相关企业：乾元浩生物股份有限公司、杭州佑本动物疫苗有限公司、金宇益康生物技术（辽宁）股份有 限公司、河南祺祥生物科技有限公司、肇庆大华农生物药品有限公司、山西 ...

证券日报网讯 2月11日，科前生物在互动平台回答投资者提问时表示，上市公司股价受宏观经济形势、 政策变化、市场情绪等多重因素综合影响。公司将坚定秉持高质量发展理念，持续加大研发投入，不断 提升经营发展能力，努力回馈投资者。 （文章来源：证券日报） ...

Core Viewpoint - The article discusses the key deployments in the 2023 Central Document No. 1, focusing on agricultural modernization through technological innovation and the development of new productive forces in agriculture [5][6][7]. Group 1: Key Deployments in Agricultural Technology Innovation - The document emphasizes strengthening integrated innovation by enhancing the overall effectiveness of the agricultural technology innovation system, promoting enterprise-led innovation, and focusing on key areas such as seeds and agricultural machinery [5]. - It highlights the expansion of application scenarios through modern information technology and biotechnology, showcasing the significant role of agricultural drones and artificial intelligence in transforming agricultural practices [6]. - The document stresses the importance of promoting the transformation of agricultural technology achievements to address practical issues faced by farmers, ensuring that innovations reach rural areas effectively [7]. Group 2: Agricultural Bio-Manufacturing Paths Worth Noting - The article identifies high-value utilization of agricultural by-products, such as straw, as a key focus, indicating a shift from mere utilization to profitable applications [8]. - It discusses the potential of synthetic biology to enhance agricultural productivity by producing essential proteins and bio-fertilizers, thereby reducing reliance on chemical fertilizers [10]. - The development of new agricultural applications, including biodegradable materials and bio-pesticides, is highlighted as a means to promote green transformation in agriculture [11]. Group 3: Market Overview of Agricultural Bio-Manufacturing - As of February 9, 2025, there are 161 companies in the A-share market related to the "synthetic biology" concept, with a total market value of approximately 1.69 trillion yuan, averaging 10.5 billion yuan per company [15]. - The agricultural bio-manufacturing sector includes around 20 companies focusing on areas such as animal vaccines and feed additives, indicating a gradual industrial application of synthetic biology in agriculture [17]. - Key companies in this sector are noted for their focus on replacing feed, plant breeding, bio-pesticides, and precision farming, showcasing the diverse applications of synthetic biology in agriculture [17].

Summary of the Conference Call Company Overview - The conference call focused on **普莱柯 (Pulaike)**, a company in the **animal vaccine industry**. The discussion highlighted the company's performance in 2025 and its outlook for 2026. Key Points and Arguments Industry Context - The animal vaccine industry has faced pressure due to fluctuations in the breeding sector and internal competition, leading to a challenging environment for many companies [1][3]. - Despite these challenges, leading companies with strong R&D capabilities have managed to achieve significant growth [1]. Financial Performance - In 2025, 普莱柯 achieved a net profit of approximately **1.176 billion to 1.95 billion** CNY, representing a year-on-year growth of **90% to 110%** [3][4]. - The company reported a nearly **50% increase** in profits during the first three quarters of 2025, driven by the release of poultry vaccine production capacity and rapid growth in the pet business [1][3]. Cost Management and Efficiency - The company has focused on cost reduction and efficiency improvements, resulting in a significant decrease in operating expenses and an increase in net profit margins [1][4][5]. - Sales expense ratios have been continuously declining, indicating effective cost control measures [5][28]. Product Development and Market Strategy - The company plans to continue its focus on high-quality, efficient growth, with expectations to maintain growth in poultry and pet products in 2026 [6][37]. - New product lines, including the **H9 series** and **cash cow series**, are expected to contribute to future growth [11][23]. Market Trends and Pricing - The pricing war in the industry has shown signs of easing, particularly for certain vaccine products, although competition remains intense [10][8]. - The company anticipates that while there may still be pressure on pricing, the overall margin for leading companies remains favorable due to their competitive advantages [10]. Sales Channels and Growth - The company has established a robust distribution network, covering **25 provinces** and over **8,000 pet hospitals** [14][15]. - The pet product segment is experiencing growth rates of over **30%**, with non-medical products seeing even higher growth [15]. Future Outlook - For 2026, the company aims to achieve a net profit target of over **2 billion** CNY, with expectations of returning to historical highs [6][7]. - The poultry vaccine segment is projected to grow by **15% to 20%**, while the pet product segment is expected to exceed **50% growth** [20][37]. Research and Development - The company is actively working on new vaccine projects, including a **African Swine Fever vaccine**, with clinical trials expected to commence soon [31][32]. - The company has made significant investments in R&D to enhance its product offerings and maintain competitive advantages [32]. Challenges and Risks - The company faces ongoing challenges from industry competition and potential impacts from disease outbreaks in livestock, which could affect sales [30][19]. - The overall market environment remains volatile, with external factors influencing the breeding sector's profitability [30]. Additional Important Information - The company has implemented a more refined management approach to sales expenses, linking spending directly to sales outcomes [28]. - There is a strategic focus on expanding international business and product registrations in various countries, aiming for significant growth in export revenues [24]. This summary encapsulates the key insights from the conference call, providing a comprehensive overview of 普莱柯's current status and future prospects in the animal vaccine industry.

Core Viewpoint - The successful completion of the first round of clinical trials for the African Swine Fever (ASF) subunit vaccine by Jinyu Biotechnology Co., Ltd. marks a historic milestone in the animal vaccine industry, providing a potential solution to a long-standing issue in global pig farming [1][2]. Group 1: Vaccine Development - The ASF virus has caused over 1 trillion yuan in economic losses to China's pig farming industry since its introduction in 2018, highlighting the urgent need for effective vaccines [2]. - Jinyu Biotechnology has invested nearly 600 million yuan over seven years in developing various vaccine technologies, including gene-deleted live vaccines, vector vaccines, subunit vaccines, and mRNA vaccines [2]. - The ASF subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs on July 14, 2025, becoming the first of its kind to enter clinical trials in China [2]. Group 2: Clinical Trial Results - The first round of challenge experiments concluded successfully in January 2026, showing a 100% survival rate in the immunized group, while the control group experienced a 100% mortality rate [3]. - The vaccine utilizes a genetically engineered subunit technology that expresses eight conserved antigen proteins without live virus, eliminating the risk of virulence reversion [3]. - The vaccine's target has a 99.7% homology with currently circulating recombinant strains, enhancing its effectiveness [3]. Group 3: Technological Integration - The success of the ASF vaccine reflects the integration of AI and biotechnology, with AI accelerating antigen screening and structural optimization [4]. - Jinyu Biotechnology has established the world's first high-throughput target library for ASF, evaluating over 100 proteins to ensure the scientific and effective design of the vaccine [4]. - The company has invested 230 million yuan to build a dedicated GMP production line with an annual capacity of 300 million doses, ensuring consistency from trial to commercialization [4]. Group 4: Future Developments - Jinyu Biotechnology aims to provide a comprehensive solution that includes smart testing, veterinary services, immune purification, and branded food products, moving beyond just vaccine sales [4][5]. - The company is also advancing other innovative vaccines, including an mRNA vaccine for feline infectious peritonitis and a novel mycoplasma vaccine for cattle, which has already been launched [5]. - Future plans include accelerating the registration process for the ASF subunit vaccine and expanding the mRNA vaccine product pipeline, while increasing investments in Southeast Asia to scale up technology, products, and services [5].